Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients.

Détails

ID Serval
serval:BIB_3C1DB6FEB256
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients.
Périodique
Journal of Heart and Lung Transplantation
Auteur(s)
Manuel O., Humar A., Berutto C., Ely L., Giulieri S., Lien D., Meylan P.R., Weinkauf J., Pascual M., Nador R., Aubert J.D., Kumar D.
ISSN
1557-3117 (Electronic)
ISSN-L
1053-2498
Statut éditorial
Publié
Date de publication
2011
Volume
30
Numéro
6
Pages
679-684
Langue
anglais
Résumé
BACKGROUND: In this study we compared the immunogenicity of influenza vaccine administered intradermally to the standard intramuscular vaccination in lung transplant recipients. METHODS: Patients were randomized to receive the trivalent inactivated seasonal 2008-9 influenza vaccine containing either 6 μg (intradermal) or 15 μg (intramuscular) of hemagglutinin per viral strain. Immunogenicity was assessed by measurement of geometric mean titer of antibodies using the hemagglutination-inhibition (HI) assay. Vaccine response was defined as a 4-fold or higher increase of antibody titers to at least one vaccine antigen. RESULTS: Eighty-five patients received either the intradermal (n = 41) or intramuscular (n = 44) vaccine. Vaccine response was seen in 6 of 41 patients (14.6%) in the intradermal vs 8 of 43 (18.6%) in the intramuscular group (p = 0.77). Seroprotection (HI ≥1:32) was 39% for H1N1, 83% for H3N2 and 29% for B strain in the intradermal group vs 28% for H1N1, 98% for H3N2 and 58% for B strain in the intramuscular group (p = 0.36 for H1N1, p = 0.02 for H3N2, p < 0.01 for B). Mild adverse events were seen in 44% of patients in the intradermal group and 34% in the intramuscular group (p = 0.38). CONCLUSIONS: Immunogenicity of the 2008-9 influenza vaccine given intradermally or intramuscularly was overall poor in lung transplant recipients. Novel strategies for influenza vaccination in this population are needed.
Mots-clé
Adult, Aged, Antibodies, Viral/blood, Female, Humans, Influenza A Virus, H1N1 Subtype/immunology, Influenza A Virus, H3N2 Subtype/immunology, Influenza B virus/immunology, Influenza Vaccines/administration & dosage, Influenza Vaccines/immunology, Influenza, Human/immunology, Influenza, Human/prevention & control, Injections, Intradermal, Injections, Intramuscular, Lung Transplantation/immunology, Male, Middle Aged, Vaccines, Inactivated/administration & dosage, Vaccines, Inactivated/immunology
Pubmed
Web of science
Création de la notice
08/03/2011 8:33
Dernière modification de la notice
20/08/2019 13:32
Données d'usage